Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.

Pont L, Alechaga É, Terrero A, Monfort N, Ventura R

Journal of chromatography. A17 Sept 2020Cited by 7 (Europe PMC)

PMID32971474DOI10.1016/j.chroma.2020.461548PepBankPUB-32971474

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01LabNot a test of CJC-1295 (with DAC) aloneOther designOther
A validated immunopurification LC-HRMS method for GHRHs including CJC‑1295 had a limit of detection of 0.2 ng/mL and a limit of identification of 0.5 ng/mL.
In plain wordsIn lab tests, a urine method could detect CJC‑1295 and related peptides at very low levels.
Peptide
CJC-1295 (with DAC)
Outcome
Not applicableLimits of detection and identification in urine
Study
n: not reported in source
Human urine samples
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
0.2 ng/mL
magnetic bead immunopurification LC-HRMS
LOI
0.5 ng/mL
magnetic bead immunopurification LC-HRMS
Source sentences
Summary
limit of detection (0.2 ng/mL) and limit of identification (0.5 ng/mL).
1 context sentence(design, population, supporting numbers)
Summary · context
In this work, we have evaluated the suitability of magnetic beads with different supports, binding capacities and affinity chemistries prior analysis of human urine samples by liquid chromatography coupled to high resolution mass spectrometry using a Quadrupole-Orbitrap instrument.
In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).
Report a problemFND-3297147401
02LabNot a test of CJC-1295 (with DAC) aloneOther designOther
The validated method for GHRHs including CJC‑1295 had intra-day imprecision below 15 % and inter-day imprecision below 25 %.
In plain wordsIn lab tests, repeat measurements of CJC‑1295 and related peptides with this urine method agreed closely.
Peptide
CJC-1295 (with DAC)
Outcome
Not applicableMethod precision
Study
n: not reported in source
Human urine samples
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Intra-day imprecision
< 15%
immunopurification LC-HRMS
Inter-day imprecision
< 25%
immunopurification LC-HRMS
Source sentences
Summary
intra- and inter-day precision (lower than 15 and 25%, respectively)
1 context sentence(design, population, supporting numbers)
Summary · context
In this work, we have evaluated the suitability of magnetic beads with different supports, binding capacities and affinity chemistries prior analysis of human urine samples by liquid chromatography coupled to high resolution mass spectrometry using a Quadrupole-Orbitrap instrument.
In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).
Report a problemFND-3297147402
03LabNot a test of Tesamorelin aloneOther designOther
A validated immunopurification LC-HRMS method for GHRHs including tesamorelin had a limit of detection of 0.2 ng/mL and a limit of identification of 0.5 ng/mL.
In plain wordsIn lab tests, a urine method could detect tesamorelin and related peptides at very low levels.
Peptide
Tesamorelin
Outcome
Not applicableLimits of detection and identification in urine
Study
n: not reported in source
Human urine samples
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
0.2 ng/mL
magnetic bead immunopurification LC-HRMS
LOI
0.5 ng/mL
magnetic bead immunopurification LC-HRMS
Source sentences
Summary
limit of detection (0.2 ng/mL) and limit of identification (0.5 ng/mL).
1 context sentence(design, population, supporting numbers)
Summary · context
In this work, we have evaluated the suitability of magnetic beads with different supports, binding capacities and affinity chemistries prior analysis of human urine samples by liquid chromatography coupled to high resolution mass spectrometry using a Quadrupole-Orbitrap instrument.
In this study, Tesamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesamorelin.
Report a problemFND-3297147403
04LabNot a test of Tesamorelin aloneOther designOther
The validated method for GHRHs including tesamorelin had intra-day imprecision below 15 % and inter-day imprecision below 25 %.
In plain wordsIn lab tests, repeat measurements of tesamorelin and related peptides with this urine method agreed closely.
Peptide
Tesamorelin
Outcome
Not applicableMethod precision
Study
n: not reported in source
Human urine samples
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Intra-day imprecision
< 15%
immunopurification LC-HRMS
Inter-day imprecision
< 25%
immunopurification LC-HRMS
Source sentences
Summary
intra- and inter-day precision (lower than 15 and 25%, respectively)
1 context sentence(design, population, supporting numbers)
Summary · context
In this work, we have evaluated the suitability of magnetic beads with different supports, binding capacities and affinity chemistries prior analysis of human urine samples by liquid chromatography coupled to high resolution mass spectrometry using a Quadrupole-Orbitrap instrument.
In this study, Tesamorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tesamorelin.
Report a problemFND-3297147404
05LabNot a test of Sermorelin aloneOther designOther
A validated immunopurification LC-HRMS method for GHRH analogs including sermorelin had a limit of detection of 0.2 ng/mL in human urine.
In plain wordsA lab method detected sermorelin and related peptides in urine at 0.2 ng/mL.
Peptide
Sermorelin
Outcome
Not applicableLimit of detection in urine
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
0.2 ng/mL
GHRH analogs in urine
Source sentences
Summary
limit of detection (0.2 ng/mL) and limit of identification (0.5 ng/mL).
1 context sentence(design, population, supporting numbers)
Summary · context
In this work, we have evaluated the suitability of magnetic beads with different supports, binding capacities and affinity chemistries prior analysis of human urine samples by liquid chromatography coupled to high resolution mass spectrometry using a Quadrupole-Orbitrap instrument.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-3297147405
06LabNot a test of Sermorelin aloneOther designOther
The method had a limit of identification of 0.5 ng/mL for GHRH analogs including sermorelin in human urine.
In plain wordsThe lab method could confirm the identity of sermorelin and related peptides in urine at 0.5 ng/mL.
Peptide
Sermorelin
Outcome
Not applicableLimit of identification in urine
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOI
0.5 ng/mL
GHRH analogs in urine
Source sentences
Summary
limit of identification (0.5 ng/mL).
1 context sentence(design, population, supporting numbers)
Summary · context
In this work, we have evaluated the suitability of magnetic beads with different supports, binding capacities and affinity chemistries prior analysis of human urine samples by liquid chromatography coupled to high resolution mass spectrometry using a Quadrupole-Orbitrap instrument.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-3297147406
07LabNot a test of Sermorelin aloneOther designOther
The method had intra-day precision below 15% and inter-day precision below 25%.
In plain wordsThe lab method gave repeatable results, with variation below 15% within a day and below 25% between days.
Peptide
Sermorelin
Outcome
Not applicableIntra- and inter-day precision
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Intra-day precision
< 15%
GHRH analogs
Inter-day precision
< 25%
GHRH analogs
Source sentences
Summary
intra- and inter-day precision (lower than 15 and 25%, respectively)
1 context sentence(design, population, supporting numbers)
Summary · context
In this work, we have evaluated the suitability of magnetic beads with different supports, binding capacities and affinity chemistries prior analysis of human urine samples by liquid chromatography coupled to high resolution mass spectrometry using a Quadrupole-Orbitrap instrument.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-3297147407

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 39Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Versions 2 to 3
9 Oct 2026, 03:13 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:13 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.